During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Julie Vose, University of Nebraska Medical Center, Omaha, US. We asked, What are the new therapeutic strategies in Mantle cell lymphoma (MCL)?
Firstly, Vose discusses the efficacy and safety of novel treatment approaches, such CAR T-cell therapy, BTKis, and bispecific antibodies in MCL; brexucabtagene autoleucel, pirtobrutinib, and bispecific antibodies (specifically epcoritamab and glofitamab) for patients with R/R MCL were then discussed. With bispecific antibodies yet to be approved for R/R MCL, there remains an unmet need for treatment options in this patient group, who may require multiple treatments throughout their lifetime.
Visit www.lymphomahub.com for more information on this topic.